# New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure

> **NCT05000853** · — · UNKNOWN · sponsor: **Hospital Universitari de Bellvitge** · enrollment: 210 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Iron Carboxymaltose

## Key facts

- **NCT ID:** NCT05000853
- **Lead sponsor:** Hospital Universitari de Bellvitge
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05000853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05000853, "New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05000853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*